AbbVie Calls For US FDA Hearing On Biosimilars Interchangeability
This article was originally published in SRA
While the US Food and Drug Administration had pledged to provide biosimilar makers with guidance in 2015 outlining what is needed for products to demonstrate interchangeability - a promise that it failed to keep - AbbVie is arguing a public hearing is needed before the agency acts on that vow1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.